ABSTRACT
Introduction
Thrombosis is a complex disorder that occurs in a chain of events including platelet adhesion, activation and aggregation, which depend on genetic and environmental factors. In the formation of a thrombus, there are predisposing factors including cardiac malformation, acquired protein defi ciency, polymorphism and genetic predisposition involved (1, 2) . Causes leading to vascular endothelial injury include atherosclerosis, infl ammation, catheterization in neonates, open operative complications and fractures of extremities, and these are the most important causes of thrombus formation (3, 4) . Healthy vascular endothelial cells ensure haemostasis through anti-thrombotic and pro-thrombotic activities. This includes the release of mediators which suppress vascular dilatation and thrombin and control the increase of fi brin, as well as accelerating the removal of free radicals (5) . As a result of trauma in the vascular endothelium, there is a decrease in the generation of anti-thrombin, fi brinogen, factors V and VIII, plasminogen activator inhibitor, thrombin, and thrombin-activated fi brinolysis inhibitor (6) . Inhibition of the fi brinolytic system is ensured by plasminogen activator inhibitors and plasmin inhibitors. When this balance is impaired, intravascular thrombosis occurs (7) . Depending on the localization and severity of thrombosis, it may cause morbidity and mortality in patients. Symptoms such as seizures, hemiparesis and coma may develop due to central nervous system thrombosis (8) .
The aim of treatment of thrombosis is to prevent local spread and the formation of emboli, both proximally and distally, to stimulate and accelerate fi brinolysis, and to prevent recurrence and post-thrombotic complications (9) . Nowadays, anticoagulants, anti-thrombocytics and thrombolytics are used for therapeutic use (10) . Enoxaparin sodium is a well-known low molecular weight heparin that is routinely used to prevent postoperative thromboses (11) . Heparin which is introduced subcutaneously or intraperitoneally decreases fi brin accumulation and thus, prevents adhesions and thrombus formation (12) .
Epidermal growth factor (EGF) is a 53-amino acid polypeptide, which was fi rst isolated from the submaxillary saliva glands of mice in the 1960s (13) . EGF exhibits a potent mitogenic effect via tyrosine-kinase receptors on cell membranes. EGF has antiinfl ammatory, anti-apoptotic, neurotrophic and neuroprotective effects (14, 15) . Furthermore, EGF accelerates the formation of granulation tissue via the stimulatory effect on growth and re-production of fi broblasts, keratinocytes and vascular endothelial cells. It enhances epithelisation and stimulates the formation of new vessels (16, 17) . The wound healing activity of EGF occurs through the mitogenic effect of binding to specifi c cell membrane receptor (HER-1) and adhering particularly to epithelial tissue, fi broblasts and vascular endothelial cells (13, 18) .
Enoxaparin is used in the treatment of thrombosis resulting from trauma-induced vascular endothelial injury, as a known anticoagulant and EGF has proven positive effects on wound healing. Therefore, the aim of this study was to investigate the potential synergic effects of enoxaparin and EGF on the formation of thrombus.
Materials and methods

Animals
The study included a total of 40 Wistar albino rats, each weighing 250-300 g and aged 9-10 weeks. The rats were given a 1-week period of adaptation to laboratory conditions before the study. The animals were kept in polypropylene cages in an environment of 21 ± 2 ºC room temperature, humidity 65-70 % and a 12-hour light/ dark cycle. They were fed standard feed and water. All the experimental phases were conducted in accordance with the approval and supervision of the Local Ethics Committee on the breeding and use of national laboratory animals. All procedures were in compliance with the principles of the Declaration of Helsinki for laboratory animals (IRB Approval No.: 2017/002-01-04).
Organization of the thrombosis model
The thrombosis model in rats was organized as in previous studies (19) . General anaesthesia was administered under aseptic conditions as intramuscular (IM) 90 mg/kg of ketamine and 10 mg/ kg of xylazine. The right posterior femoral artery of each rat was used for the thrombosis model. The vessel was exposed through the incision made in the region and freed from the surrounding tissue. A tampon impregnated with 20 % Ferric Chloride (FeCl) was topically applied, as specifi ed in literature, on the vessel as shown in Figure 1 . To prevent the FeCI causing any damage to surrounding muscular and nervous tissues, the tampon was surrounded with aluminium foil as shown in Figure 1A . When cyanosis was observed on the vessel (Fig. 1B) , the tampon was removed and the wounds of the experimental animals were left for secondary healing following appropriate wound site closure.
Study design
The rats were randomly divided into 5 groups of 8. With the exception of the Sham group (Group 1) the thrombosis model and treatment was applied to the other 4 groups as follows:. Group 1 Sham): No damage was induced.
Group 2 (PBS): 1 ml of PBS was administered intraperitoneally (IP).
Group 3 (Enoxaparin): Subcutaneous (SC) injection of Enoxaparin Sodium (Clexane®, Sanofi -Aventis) at a dose of 2 mg/kg. Group 4 (EGF): 1 ml of EGF (Heberprot-P© 75 μg) was administered IP.
Group 5 (EGF+Enoxaparin): Enoxaparin Sodium (Clexane®, Sanofi -Aventis) at a dose of 2 mg/kg was administered SC and 1 ml of EGF was administered IP.
The initial treatments were applied 2 hours preoperatively, then a second treatment was applied at 48 hours postoperatively. The rats were sacrifi ced on the 7th day after the second treatment. The right femoral region, where the thrombosis was induced, was incised and the damaged vessel was dissected. Tissue samples were fi xed in 10 % neutral formaldehyde (pH 7.2-7.4) for histopathological and immunohistochemical studies.
Histopathological examination
The fi xed vascular tissues were soaked under running water to remove the formaldehyde and were then dehydrated with increasing grades of ethanol (50 %, 75 %, 96 %, 100 %) in an automated tissue follow-up device. Xylol staining was applied and the samples were blocked in a paraffi n embedding device. Of the slices 4 microns in thickness cut from these blocks, the fi rst three slices and every tenth slice were transferred onto a microscope slide via Leica RM 2125 RT for examinations under light microscope. The prepared preparations were passed through a graded alcohol and xylol series and then stained with hematoxylin-eosin A B (HE) and trichrome staining. All samples were examined under a high-resolution light microscope (Olympus DP73 camera, Olympus BX53-DIC microscope; Tokyo, Japan) at x40 to x100 magnifi cation for thrombosis wall diameter, neovascularisation localized around the thrombus and formation of new canals within the thrombus. The differences between the groups were evaluated.
Immunohistochemical examination
Neovascularisations around the thrombus were stained using vWF, VEGF and CD34 primary antibodies, to determine an increase in endothelial cells around the thrombus. CD68 primary antibody was used to determine macrophage intensity in this region, Accordingly, slices 4 microns in thickness were cut from the paraffi n blocks and transferred onto Poly-L-lysine-coated microscope slides; after routine deparaffi nization and rehydration methods. Staining was applied in accordance with the streptavidin-biotin-peroxidase complex (ABC) method (Zymed, Histostain Plus Kit, California, USA). For antigenic retrieval in tissues, heat treatment with citrate buffer (pH 6.0) was applied in a microwave oven for 20 minutes. Endogenous peroxidise activation within the tissues was blocked for 10 minutes with 0.3 % hydrogen peroxide in methanol within 0.01M PBS. Prior to primary antibodies, the tissues were incubated with 5 % normal goat serum for 30 minutes and protein blocking was performed. Then with incubation for 60 minutes, the slices were marked with anti-VWF (1 : 200; 36B11, Leica, Newcastle, UK), anti-VEGF (1 : 50; ab32152, Abcam, Cambridge, UK), CD68 (1 : 100; 514H12, Leica, Newcastle, UK) and CD34 (1 : 100; QBEnd/10, Leica, Newcastle, UK) primary antibodies under room temperature. Then the tissues were incubated for 30 minutes with rabbit antimouse biotinylated secondary antibody, and left for a further 30 mins incubation with streptavidin-peroxidase conjugate. In order to make the reaction visible, diaminobenzidine (DAB, Dako/ Denmark) chromogen was dropped onto the slices and left for 10 minutes. Finally, after staining with hematoxylin for posterior staining, the samples were soaked under running water. The tissues were passed through graded alcohol and xylol series and then adhered using Entellan. The whole staining procedure was conducted under room temperature and in humidity chambers. In the staining phases, PBS solution was used to soak the slices. The obtained data were evaluated under high-resolution microscope (Olympus DP73 camera, Olympus BX53-DIC microscope; Tokyo, Japan). For each sample, immunopositive cells determined at x40 and x100 magnifi cations were counted, recorded and then statistically evaluated.
Statistical analysis
All data analyses were applied using SPSS vn 24.0 for Windows software. Conformity to normal distribution of the data was tested using the Shapiro-Wilk Test. In the comparison of variables without normal distribution in more than two groups, the Kruskal Wallis test and Dunn's multiple comparison tests were used. Median (25-75 %) values were used as descriptive statistics. A value of p < 0.05 was accepted as statistically signifi cant.
Results
Histopathological results
A statistically signifi cant histological level of regression in thrombus resolution in the EGF + Enoxaparin group compared to the control and other groups was also statistically determined on fi gures (p < 0.05) (Fig. 2) . The volume of thrombus was signifi cantly lower in the EGF+Enoxaparin group compared to the other groups (p < 0.05) (Fig. 3) . A signifi cant regression in volume of thrombus was determined in the Enoxaparin group compared to the EGF and control groups (p < 0.05) (Fig. 4) . Recanalization formations were found to be signifi cantly higher in the EGF+Enoxaparin group compared to the other groups (p < 0.05). Recanalization formations were signifi cantly higher in the Enoxaparin thrombosis group compared to the EGF and control groups (p < 0.05) (Fig. 5) . Neovascularizations were at the highest level in the EGF+ Enoxaparin group compared to the other groups (p < 0.05) and statistically signifi cantly higher in the EGF group compared to the control group (p < 0.05). No neovascularisation was determined in the Enoxaparin group (p > 0.05) (Fig. 6) .
Immunohistochemical results
Immunohistochemically, in the VEGF and vWF staining procedures, immunoreactive cell intensity determined around the thrombus was determined to be at a signifi cantly high level in rats 
Discussion
Thrombosis is an important complication which occurs from damage developing in the vessel wall and may be life-threatening. Anti-thrombotics or anticoagulants are used to prevent the potential formation of a thrombus and for treatment of thrombosis, (20, 21). The aim of thrombosis treatment is to prevent local spread and the formation of emboli, and to increase the recanalization rate by accelerating the organization of a thrombus (22) . Thrombotic medications are plasminogen activators which catalyze conversion to plasmin, which is involved in the degradation of endogenous plasminogen into fi brin (10) . Fibrinolytic treatment, however, occurs through degradation of fi brin, which is the major component in a clot, by plasmin which is activated through intravenous, intra-arterial or direct administration of plasminogen activators into the clot treated with EGF+Enoxaparin compared to the EGF only group (p < 0.05) (Fig. 3A) . VEGF-positive cell intensity was determined to be statistically signifi cantly higher in the EGF+ Enoxaparin group compared to the other groups (p < 0.05) (Fig. 7) . vWFimmunopositive cell intensity was observed to be statistically signifi cantly higher in the EGF+ Enoxaparin group compared to the other groups (p < 0.05) (Fig. 3B, Fig. 8 ). CD 34 antibody-positive cell intensity was observed to be statistically signifi cantly higher in the EGF+ Enoxaparin group compared to the other groups (p < 0.05) (Fig. 3C, Fig. 9 ). Macrophage accumulation (CD68) around the thrombus was determined to be statistically signifi cantly higher in the EGF+Enoxaparin group compared to the Enoxaparin only and control groups (p < 0.05) (Fig. 3D, Fig. 10 ), and no statistical signifi cance was found between the EGF+Enoxaparin and EGF treatment groups (p > 0.05). per fi eld, 100x) . (23) . In a previous study, it was observed that Enoxaparin sodium, which is a low molecular weight heparin component with proven effectiveness, promoted the formation of new canals by accelerating thrombus resolution with a fi brinolytic effect (9, 11). It was determined that when Enoxaparin was used alone, the number of canals increased and the volume of the thrombus regressed, although neovascularisation did not occur. In addition, it was noticeable that when used with EGF, there was both a marked increase in the formation of canals and a signifi cant reduction in thrombus volume.
In recent studies, it has become obvious that various new approaches have been sought for the preservation and treatment of thrombosis. Varma et al (24) reported in an experimental study that there was a signifi cant increase in numbers of recanalization in basic fi broblast growth factor (bFGF) treatment but it had no effect on the organization of thrombus. Waltham et al (25) reported that VEGF treatment enhanced neovascularisation and recanalization, and helped regression of thrombus. Previous studies have determined that defi brotid triggers the formation of new canals and reduces the volume of thrombus via a fi brolytic effects in thrombosis (19) . In the current study, however, with concomitant application of EGF and Enoxaparin, both healing of the vascular injury through repair and the prevention of recurrence of thrombosis were ensured, and a double-sided treatment was applied ensuring rapid resolution of the thrombus. In a similar experimental rat model study by Dilli et al (19) it was reported that with stem cell treatment, there was an increase in numbers of recanalizations and neovascularisations of thrombus and a signifi cant reduction of the thrombus volume.
Organization in tissue damage has a complex structure involving various factors. Fibroblast activation, macrophage accumulation and endothelial cell proliferation in particular have important roles in wound healing (26, 27, 28) . Endothelium, fi broblast and smooth muscle cells have receptors secreted by EGF. These receptors exhibit a chemotactic effect by stimulating DNA synthesis on these cells, as well as accelerating wound healing by ensuring stimulation of angiogenesis and collagenesis (16, 17) . EGF applications are successful especially in the treatment of wounds because of the stimulatory effect on growth and reproduction of fi broblasts, keratinocytes and vascular endothelial cells. Tarnawski and Jones (29) determined positive effects of EGF in the healing of ulcers which develop in the gastrointestinal system. Procaccino et al (30) also determined that experimentally, EGF reduced infl ammation and accelerated mucosal repair in the healing of colitis and duodenal ulcers. Tuyet et al (31) reported that EGF application accelerated vascularisation and had positive effects on wound healing in diabetic patients where the healing of foot wounds is particularly challenging. Kennedy et al (14) reported that EGF suppressed renal tubular apoptosis following ureteral obstruction. It has been determined that EGF enhances healing and regeneration in ischemic renal injury induced in experimental rats (32, 33) .
Many studies have also shown the positive effects through stimulation of epithelisation and vascularisation of EGF in burn injury treatment (16, 17, 28, 30) . EGF has effects on wound healing with its infl ammatory, fi broblastic activation and remodelling in all cases of tissue damage (28, 30) . The organization and resolution of a thrombus which has formed as a result of a vascular injury has the characteristics of general wound healing (34). In the current study, it was also observed that EGF has a healing effect on vessels and on neovascularisation. In the literature, there are few studies on the effect of EGF on vessels. In one study, it was shown that EGF enhanced healing in the damaged artery and thereby exhibited a vasoprotective effect. In another study which examined neovascularisation it was demonstrated that EGF promoted angiogenesis in the same way as VEGF and FGD (35).
The current study results, in agreement with the fi ndings of previous studies determined that EGF enhanced neovascularisation and the organization of thrombus, in a similar way to wound healing and the vessel wall injury was repaired by promoting macrophage accumulation. The current study also showed that neovascularization, which is one of the important markers of wound healing in particular, signifi cantly increased around the thrombus together with both histological and immunohistochemical markers. It was also determined that in the group with signifi cant organization of thrombus, macrophage accumulation was immunohistochemically strong and CD68 antibody-immunopositive cells were present at the site of the thrombus. Furthermore, with the well-known thrombolytic effect of Enoxaparin, a reduction in volume of the thrombus and an increase in the number of new canals were observed.
In conclusion, the effectiveness of EGF in the treatment of thrombosis was recognized in this study. This histopathological and immunohistochemical study conducted with EGF revealed that EGF accelerated healing in the thrombosed vessel wall, triggered neovascularisation and was therefore effective in organization of the thrombus. It was also determined that when used concomitantly with Enoxaparin, which is an anticoagulant agent, a synergistic effect occurred and thrombus resolution was accelerated. All these fi ndings indicate that EGF may be used in the treatment of thrombosis. 
Learning points
• Epidermal growth factor reduced the harmful effects of thrombosis.
• Vessel wall healing activities are likely to be involved in the mechanism underlying the formation of thrombus.
• Epidermal growth factor can be considered for use as a wound healing agent for thrombosis.
